MedPath

A comparative study between two groups of randomly chosen newborn babies to see the effects of hydrocortisone in shock when given early (along with first line vasopressor agents) versus standard timing (failure of vasopressor drugs to maintain blood pressure).

Phase 4
Completed
Conditions
Health Condition 1: null- Neonates with shock
Registration Number
CTRI/2016/09/007276
Lead Sponsor
Sankalp Dudeja
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
84
Inclusion Criteria

Any neonate less than 44 weeks post-menstural age, presenting with clinical shock.

Exclusion Criteria

a) Clinical setting of dehydration/ obvious blood loss

b) Hypoxic ischemic encephalopathy- moderate to severe

c) Suspected or proven duct dependent systemic/pulmonary circulation

d) Neonates received postnatal steroids in the past 7 days

e) Suspected or proven congenital adrenal hyperplasia

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
All cause mortalityTimepoint: Within 14 days of onset of shock.
Secondary Outcome Measures
NameTimeMethod
Abdominal distension, Altered aspirates, hematemesis, hyperglycemia or hypertensionTimepoint: Within 72 hours of drug administration;Functional echocardiographic markers of systolic and diastolic functions viz left ventricular systolic functions (Cardiac output, Ejection Fraction, Fractional Shortening, End Systolic Wall Stress (ESWS), Heart Rate corrected velocity of circumferential fiber shortening (VCFc), E:A ratio, and IVRT)Timepoint: At baseline (Preferably before initiation of vasopressor drugs or within one hour of their initiation) and 4-6 hours after giving trial drug.;Incidence of Catecholamine resistant shockTimepoint: During that episode of shock;Incidence of definite NEC, ROP, BPD and PVLTimepoint: During the hospital stay;Inotrope score and duration of inotropes/ vasopressorsTimepoint: During that episode of shock
© Copyright 2025. All Rights Reserved by MedPath